Skip to main content
Featured Scientist
Author published in"npj Primary Care Respiratory Medicine"affiliate to

College of Medicine

Cheng-Yi Wang 

School of Medicine, 

Fu Jen Catholic University, New Taipei City, Taiwan

Article published in

"NPJ Prim Care Respir Med" 2021 Apr 20;31(1):19


The prevalence and outcome of short-acting β2-agonists overuse in asthma patients in Taiwan

This study aims to investigate the prevalence of short-acting β2-agonist (SABA) overuse in asthma and the associated risk of acute exacerbation and mortality in Taiwan. We used the Taiwanese pay-for-performance asthma program database, which included patients aged between 12 and 100 years who were enrolled in the program between 2001 and 2015. Among a total of 218,039 patients, 34,641 (15.9%) patients are classified as SABA over-users. Compared with patients who did not receive inhaled corticosteroids (ICS) and collected ≤2 canisters, SABA over-users had a higher risk of severe exacerbations. SABA over-users had a higher risk of all-cause mortality compared with patients who did not receive ICS and collected ≤2 canisters. The overall prevalence of SABA overuse in Taiwan is 15.9%, and this is even higher in concomitant ICS users. In addition, the overuse of SABA is associated with an increased risk of severe exacerbation and death.

Figure1           Figure2

 

11 views
Scroll